Oxycodone naloxone

also known as OXN · OXN PR · Targin

Developed for: constipation disorder · neuropathy, painful · osteoarthritis
Investigated by: Admescope Ltd · Kuopio University Hospital · Mundipharma Research GmbH & Co KG

today NCT02571881 · Ph 4 NCT00902837 · Ph 3

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 31 trial
Phase 3	NCT00902837	May 2009 → Apr 2010	osteoarthritis	Mundipharma Research GmbH & Co KG	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT02571881	Oct 2012 → Dec 2023	constipation disorder, neuropathy, painful	Kuopio University Hospital	Unknown	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 0	NCT06212830 Comparator	Feb 2024 → Feb 2025	—	Assaf-Harofeh Medical Center	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Oxycodone naloxone	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00902837 ↗ 1 NCT02571881 ↗
Known as	OXN	“Oxycodone naloxone prolonged release tablets (OXN)” NCT00902837 ↗
Known as	OXN PR	“Subjects with moderate to severe pain due to osteoarthritis (OA) will be randomised to oxycodone/naloxone prolonged release (OXN PR) or oxycodone prolonged release tablets...” NCT00902837 ↗
Known as	Targin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06212830 ↗